Company Profile for Madeira Therapeutics
* Reuters is not responsible for the content in this press release.
--(Business Wire)--
Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company
focused on providing safe and effective medicine to pediatric and geriatric
patients, parents and the healthcare professionals that serve them. The Madeira
strategy focuses on reformulating adult drugs for better dosage control in
children. Madeira utilizes the FDA`s 505(b)(2) approval method, which relies in
part on the regulatory agency`s findings for a drug previously approved for
adults, thereby shortcutting FDA approval by years and saving tens of millions
of dollars in development costs. The company`s lead program, MT-001, is the
first ever liquid preparation of a statin developed for the geriatric and
pediatric population. The second product is MT-003 for acute pain relief. For
more information, please visit www.madeiratherapeutics.com.
Company: Madeira Therapeutics
Headquarters Address: 4745 W. 136th Street
Suite #102
Leawood, KS 66224
Main Telephone: (913) 661-1962
Website: www.madeiratherapeutics.com
Type of Organization: Private
Industry: Biotechnology
Key Executives: CEO: Pete Joiner
CEO
Contact: Pete Joiner
Phone: 913-661-1962
Email: pjoiner@madeiratherapeutics.com
Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters